Industry welcomes India regulator notice on academic trials

Research

A notice by the Drug Controller General of India (DCGI) has paved the way for a variety of much needed new clinical research by academics on already approved drugs, the Indian Society for Clinical Research (ISCR) said.

The DCGI acted on a pending request from the Indian Council of Medical Research (ICMR) to support an exemption on ethics committee-approved academic trials covering new indications, routes of administration, and dose or dosage form of approved drug formulations--helping to break a logjam on trials in those areas, particularly in the cases of medicines to treat tuberculosis, malaria and cancer.

ISCR, a professional association which includes multinationals and CROs, told the Financial Express newspaper that it welcomed the move and said it would spur academic work in drug development.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“Our academic and teaching institutions are engaged in path-breaking research that addresses the unique health challenges of our country,” Shashwati Pramanik, chair of the ISCR Regulatory Council, told the newspaper.

In January, the ISCR released a report that advocated a central online filing system in India--akin to clinicaltrials.gov in the U.S.--and a process of pre-submission meetings with the DGCI to smooth out the process. The industry body has also adopted a more robust informed consent process that includes video and audio recordings of potential patients, particularly those that are considered "vulnerable" because of language or other barriers.

Clinical trials in India faced a backlash in the past few years as public-interest lawsuits questioned the fairness of the process. A 2012 case that went to the Supreme Court of India raised questions on informed consent and related ethical guidelines for compensation in the event of injury or death.

In January, a report said India had 6,520 clinical trials in progress.

- here's the story from Financial Express

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.